Fig. 4: Risankizumab downregulates IL-17 signaling by reducing CD8⁺ T_RM cells.

a UMAP plot showing T cells colored by subtypes. b UMAP plots showing the expression levels of CD8A, CD4, ITGAE, CD69, IL17A, IL22, IFNG, and CCR6 in the T cell subtypes. c Plot showing the cell abundance in CD8 + TRM1 and CD8 + TRM17 following treatment with 300 or 600 mg of risankizumab. Every dot represents a patient. Lesional baseline (n = 13), non-lesional baseline (n = 12), 300 mg (n = 8) and 600 mg of risankizumab (n = 5) (one-way ANOVA). d Dot plot showing IL17A, IL17F, and IL22 expression comparing post-treatment (300 and 600 mg) to baseline in the CD8 + TRM17. e Violin plot showing the tissue-resident module score in CD8⁺ T cell subtypes. In the box plot, the centerlines denote median values (50th percentile); the bounds of the boxes represent the first and third quartiles (25th and 75th percentiles); the whiskers indicate the smallest and largest values within 1.5× the interquartile range. f Pseudotime trajectory colored by the pseudotime. g Pseudotime trajectory colored by three CD8⁺ T cell subtypes. h Expression of transcriptional signature plotted over pseudotime. i Pseudotime trajectory colored by three CD8⁺ T cell subtypes, split into different groups.